These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26254368)

  • 21. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.
    Vingerhoeds MH; Steerenberg PA; Hendriks JJ; Dekker LC; Van Hoesel QG; Crommelin DJ; Storm G
    Br J Cancer; 1996 Oct; 74(7):1023-9. PubMed ID: 8855969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
    Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
    Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
    Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
    J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells.
    Wöll S; Dickgiesser S; Rasche N; Schiller S; Scherließ R
    Eur J Pharm Biopharm; 2019 Mar; 136():203-212. PubMed ID: 30677497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging.
    Jeong HY; Kang SJ; Kim MW; Jeong IH; Choi MJ; Jung C; Song IH; Lee TS; Park YS
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer.
    Wagener M; Zhang X; Villarreal HG; Levy L; Allen P; Shentu S; Fang B; Krishnan S; Chang JY; Cheung MR
    Oncol Rep; 2008 May; 19(5):1071-7. PubMed ID: 18425360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
    Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
    Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
    Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
    Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
    Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo.
    del Carmen MG; Rizvi I; Chang Y; Moor AC; Oliva E; Sherwood M; Pogue B; Hasan T
    J Natl Cancer Inst; 2005 Oct; 97(20):1516-24. PubMed ID: 16234565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer.
    Zhang Y; Zhang YF; Bryant J; Charles A; Boado RJ; Pardridge WM
    Clin Cancer Res; 2004 Jun; 10(11):3667-77. PubMed ID: 15173073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles.
    Cui C; Xue YN; Wu M; Zhang Y; Yu P; Liu L; Zhuo RX; Huang SW
    Biomaterials; 2013 May; 34(15):3858-69. PubMed ID: 23452389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment and evaluation of cancer-specific human monoclonal antibody GAH for targeting chemotherapy using immunoliposomes.
    Hosokawa S; Tagawa T; Niki H; Hirakawa Y; Ito N; Nohga K; Nagaike K
    Hybrid Hybridomics; 2004 Apr; 23(2):109-20. PubMed ID: 15165484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.